NBDC Research ID: hum0381.v1
SUMMARY
Aims: We explore biomarkers of nivolumab efficacy and safety in patients with unresectable or recurrent thymic carcinoma. In order to perform multifaceted analysis using blood and tumor tissue specimens, pathological evaluation, pharmacokinetic, and molecular imaging analysis, genomic analysis, and immunomonitoring were performed.
Methods: We analyze immune-related genes (SNV, indel analysis and function prediction, copy number mutation analysis, etc.) by Immuno-PGx panel with peripheral blood cell components.
Participants/Materials: 15 patients with thymic carcinoma participating in the NCCH1505 study
Dataset ID | Type of Data | Criteria | Release Date |
---|---|---|---|
JGAS000588 | NGS (Target Capture) | Controlled-access (Type I) | 2023/01/05 |
* Data users need to apply an application for Using NBDC Human Data to reach the Controlled-access Data. Learn more
Participants/Materials | thymic carcinoma (ICD10: C37) : 15 cases |
Targets | Target Capture |
Target Loci for Capture Methods | Immuno-PGx panel |
Platform | Illumina [NextSeq 500] |
Library Source | DNAs extracted from peripheral blood cells |
Cell Lines | - |
Library Construction (kit name) | Sure Select XT Library Prep Kit |
Fragmentation Methods | Ultrasonic fragmentation (Covaris) |
Spot Type | Paired-end |
Read Length (without Barcodes, Adaptors, Primers, and Linkers) | 101 bp |
Japanese Genotype-phenotype Archive Dataset ID | JGAD000715 |
Total Data Volume | 17.1 GB (fastq) |
Comments (Policies) | NBDC policy |
DATA PROVIDER
Principal Investigator: Hidehito Horinouchi
Affiliation: Department of Thoracic Oncology, Nantional Cancer Center Hospital
Project / Group Name: -
Funds / Grants (Research Project Number):
Name | Title | Project Number |
---|---|---|
Practical Research for Innovative Cancer Control, Japan Agency for Medical Research and Development (AMED) | Study to Expand Indication of Nivolumab, an Anti-PD-1 Antibody, for Thymic Carcinoma and Thymoma | JP17ck0106161 |
PUBLICATIONS
Title | DOI | Dataset ID | |
---|---|---|---|
1 | Comprehensive biomarker analysis from phase II study of nivolumab in patients with thymic carcinoma | doi: 10.3389/fonc.2022.966527 | JGAD000715 |
2 |
USRES (Controlled-access Data)
Principal Investigator | Affiliation | Country/Region | Research Title | Data in Use (Dataset ID) | Period of Data Use |
---|---|---|---|---|---|